French pharmaceutical giant Sanofi has entered into exclusive negotiations with US-based private equity firm Advent International to divest its European generics business Zentiva for €1.9bn.
Following the binding deal, the two companies plan to jointly work to establish a new independent operation.
Zentiva offers a wide range of generic medicines across various therapeutic areas. The business caters to more than 40 million patients throughout 25 European countries.
Advent International European healthcare managing director and co-head Tom Allen, and French division managing director and head Cédric Chateau jointly commented: “We have long been attracted to the generics pharmaceutical sector as it enables more people to access high quality treatments by lowering their cost.
“We believe that Zentiva is a great platform, full of talented people, who we can invest behind to build a new, independent, European generics leader.”
Advent will support the management at Zentiva through investment in operations, production facilities, and the research and development pipeline.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Sanofi CEO Olivier Brandicourt said: “Zentiva is a robust business with a highly talented workforce and we believe it has demonstrated its potential for growth.
“Following a comprehensive review of strategic options for our generic unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success.”
Subject to the finalisation of definitive agreements and regulatory approvals, the acquisition is expected to be completed by the end of this year.